Vor Biopharma Inc. (VOR) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Vor Biopharma Inc.
Address
500 Boylston Street
Boston, MA 02116
United States of America (the)
Phone
617 655 6580
Website
Sector
Healthcare
Industry
Biotechnology
Employees
76
First IPO Date
February 05, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Jean-Paul Kress | Chairman, President & CEO | 1.01M | 1965 |
| Sandesh Mahatme | Chief Business Officer & Chief Financial Officer | 603,814 | 1965 |
| Jeremy Sokolove | Chief Medical Officer | 695,160 | 1974 |
| Robert Ang MBBS | Strategic Advisor | 2M | 1975 |
| Navid Z. Khan | Chief Medical Affairs Officer | 0 | N/A |
| Siddhartha Mukherjee DPHIL | Scientific Founder & Chairman of Scientific Advisory Board | 0 | 1971 |
| Adi Osovsky | General Counsel | 0 | N/A |
| Carol Lincoln | Head of Human Resources | 0 | N/A |
| Dallan Murray | Chief Commercial Officer | 0 | 1970 |
Description
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
